Physician profile
Robert Antoine
NPI 1245249218
$1,941.04
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,133 · 2020: $338 · 2021: $379 · 2022: $90.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $501.35 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $294.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $200.83 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $116.11 | 2019-2022 | |
| Bausch Health US, LLC | $106.34 | 2019-2021 | |
| Lundbeck LLC | $102.33 | 2019-2021 | |
| Gilead Sciences, INC. | $88.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.62 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $72.84 | 2019 | |
| Neurocrine Biosciences, INC. | $60.83 | 2019-2020 | |
| Alkermes, INC. | $56.02 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $49.66 | 2019 | |
| Neuronetics, INC. | $44.59 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.95 | 2021 | |
| Almatica Pharma LLC | $29.79 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $22.29 | 2019 | |
| Abbvie INC. | $22.13 | 2022 | |
| Brainsway USA INC | $19.55 | 2019 | |
| Indivior INC. | $15.62 | 2022 | |
| Merck Sharp & Dohme LLC | $14.70 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Antoine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.